Cantor Fitzgerald Reiterates Neutral on Pacific Biosciences, Maintains $14 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Ross Osborn has reiterated a Neutral rating on Pacific Biosciences (NASDAQ:PACB) and maintained a $14 price target.
August 22, 2023 | 3:42 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cantor Fitzgerald has reiterated a Neutral rating on Pacific Biosciences and maintained a $14 price target.
The news is directly about Pacific Biosciences and its stock rating by Cantor Fitzgerald. The Neutral rating suggests that the analyst does not expect significant price movement in the short term. The maintained price target indicates that the analyst's valuation of the company has not changed.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100